{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30","value":"8700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 1/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"9780"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 2/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"10200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 1/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44","value":"11300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 2/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"10200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 1/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45","value":"11300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 2/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"119","value":"13800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 1/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"170","value":"12500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 2/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"192","value":"18300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 1/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"217","value":"14800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 2/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"193","value":"18400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 1/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"253","value":"15700"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 2/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"26200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 1/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"22100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 2/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"32200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 1/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"27300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 2/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21","value":"32300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 1/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"27500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 2/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"28900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 1/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"23500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 2/Day 2, AUC(0-24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36","value":"38100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 1/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44","value":"30800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 2/Day 2, AUC(0-tlast)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"38300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 1/Day 2, AUC(0-∞)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44","value":"30900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 2/Day 2, AUC(0-∞)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"AUC from time zero to 24 hours (AUC\\[0-24\\]), AUC from time zero to the last time point with a measurable concentration (AUC\\[0-tlast\\]), and AUC from time zero to infinity (AUC\\[0-∞\\]) values are reported for each LY2603618 dose level on Cycle 1 /Day 2 and Cycle 2 /Day 2. The number of pharmacokinetic observations (n) used in the analysis is presented for each dose level and time point.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles 1-2 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 130 to 275 mg\n\nAfter 2 cycles, participants may have continued on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 1: Pemetrexed + Cisplatin + LY2603618"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Phase 1 participants who received at least 1 dose of LY2603618 and had samples collected for pharmacokinetic analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1/Day 2 - immediately prior to end of LY2603618 infusion and 1, 3, 6, 24, 48, 72, and 144 hours postdose; Cycle 2/Day 2 - predose, immediately prior to end of LY2603618 infusion, and 1, 3, 6, 24, 48, 72, and 144 hours postdose","title":"Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618)","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}